Next Gen rAAV Production – A Scalable Platform To Revolutionize Gene Therapy Manufacturing

Recombinant adeno-associated virus (rAAV) vectors have become indispensable tools in gene therapy, offering efficient delivery of therapeutic payloads. However, the production of these vectors presents substantial challenges, particularly in scaling up to meet clinical demands.

By leveraging one-factor-at-a-time (OFAT) studies and multivariate design-of-experiments (DOE) testing, ReciBioPharm's rAAV manufacturing platform achieves impressive rAAV8 titers of up to 2E15 GC/L with over 40% full capsids. This robustness extends across a variety of serotypes and genome lengths, ensuring broad applicability in clinical settings. The platform's versatility is further demonstrated through successful scale-up processes and optimization of transfection parameters.

This poster details the development, optimization, and validation of ReciBioPharm’s rAAV production system, underscoring its potential to revolutionize gene therapy manufacturing and meet the growing demand for high-quality viral vectors.